These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 32952)
41. The history of dopamine and levodopa in the treatment of Parkinson's disease. Fahn S Mov Disord; 2008; 23 Suppl 3():S497-508. PubMed ID: 18781671 [TBL] [Abstract][Full Text] [Related]
42. [Mortality in Parkinson's disease and its modification by levodopa (author's transl)]. Schneider E; Fischer PA; Jacobi P; Kolb R Fortschr Neurol Psychiatr; 1981 May; 49(5):187-92. PubMed ID: 7239405 [No Abstract] [Full Text] [Related]
43. Mitochondrial respiratory chain function in multiple system atrophy. Gu M; Gash MT; Cooper JM; Wenning GK; Daniel SE; Quinn NP; Marsden CD; Schapira AH Mov Disord; 1997 May; 12(3):418-22. PubMed ID: 9159739 [TBL] [Abstract][Full Text] [Related]
44. [Recent progress in treatment of Parkinson's disease]. Narabayashi H Nihon Rinsho; 1990 Dec; 48(12):2943-50. PubMed ID: 2086859 [No Abstract] [Full Text] [Related]
45. Myths and realities of continuous dopaminergic stimulation. Pirtošek Z Psychiatr Danub; 2011 Mar; 23(1):80-3. PubMed ID: 21448103 [TBL] [Abstract][Full Text] [Related]
47. Pharmacotherapy of Parkinson's disease: research from 1960 to 1991. Pletscher A; DaPrada M Acta Neurol Scand Suppl; 1993; 146():26-31. PubMed ID: 8101413 [TBL] [Abstract][Full Text] [Related]
48. Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease. Fariello RG Drugs; 1998; 55 Suppl 1():10-6. PubMed ID: 9483165 [TBL] [Abstract][Full Text] [Related]
49. Normal substantia nigra patients treated with levodopa - Clinical, therapeutic and pathological observations. Rajput AH; Rajput ML; Robinson CA; Rajput A Parkinsonism Relat Disord; 2015 Oct; 21(10):1232-7. PubMed ID: 26372624 [TBL] [Abstract][Full Text] [Related]
50. Presynaptic dopamine depletion determines the timing of levodopa-induced dyskinesia onset in Parkinson's disease. Yoo HS; Chung SJ; Chung SJ; Moon H; Oh JS; Kim JS; Hong JY; Ye BS; Sohn YH; Lee PH Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):423-431. PubMed ID: 29075830 [TBL] [Abstract][Full Text] [Related]
51. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate. Fleming SM; Delville Y; Schallert T Behav Brain Res; 2005 Jan; 156(2):201-13. PubMed ID: 15582106 [TBL] [Abstract][Full Text] [Related]
52. Parkinson's disease: progress and controversies. Lee RG Can J Neurol Sci; 1991 Feb; 18(1):69. PubMed ID: 1674669 [No Abstract] [Full Text] [Related]
57. [Parkinson's disease: some physiopathologic aspects and clinical practice]. Agid Y Rev Prat; 1989 Mar; 39(8):641-6. PubMed ID: 2567050 [TBL] [Abstract][Full Text] [Related]
58. The rationale for continuous dopaminergic stimulation in patients with Parkinson's disease. Sage JI; Mark MH Neurology; 1992 Jan; 42(1 Suppl 1):23-8; discussion 57-60. PubMed ID: 1347908 [TBL] [Abstract][Full Text] [Related]
59. Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease. Scherfler C; Esterhammer R; Nocker M; Mahlknecht P; Stockner H; Warwitz B; Spielberger S; Pinter B; Donnemiller E; Decristoforo C; Virgolini I; Schocke M; Poewe W; Seppi K Brain; 2013 Oct; 136(Pt 10):3028-37. PubMed ID: 24014521 [TBL] [Abstract][Full Text] [Related]
60. The protective role of levodopa in the human substantia nigra. Rajput AH Adv Neurol; 2001; 86():327-36. PubMed ID: 11553992 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]